1-8 of 8
Natalie Cureton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I. Fisher, Eric T. Gangl, Hilary Lewis, Dawn Trueman, Neha Wali, Stuart C. Williamson, Jennifer Moss, Elodie Montaudon, Heloise Derrien, Elisabetta Marangoni, Ricardo J. Miragaia, Sladjana Gagrica, Pablo Morentin-Gutierrez, Thomas A. Moss, Gareth Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E. Critchlow, James S. Scott, Justin P.O. Lindemann, Simon T. Barry, Teresa Klinowska, Christopher J. Morrow, Larissa S. Carnevalli
Journal: Cancer Research
Cancer Res (2023) 83 (23): 3989–4004.
https://doi.org/10.1158/0008-5472.CAN-23-0694
Published: 01 December 2023
View article titled, The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Open the PDF for The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract PD10-04: PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors

Larissa Carnevalli, Susana Ros, Jelena Urosevic, Natalie Cureton, Sophie Darcy, Mandy Lawson, Stuart Williamson, Pablo Morentin Gutierrez, Azadeh Bashi, Jennifer Moss, Christopher Morrow, Barry Simon, Teresa Klinowska
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD10-04.
https://doi.org/10.1158/1538-7445.SABCS22-PD10-04
Published: 01 March 2023
View article titled, Abstract PD10-04: PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors
Journal Articles

Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α

Christopher Morrow, Larissa Carnevalli, Richard D. Baird, Tim Brier, Carmela Ciardullo, Natalie Cureton, Mandy Lawson, Robert McEwen, Myria Nikolaou, Anne Armstrong, Begoña Bermejo, Emiliano Calvo, Eva Ciruelos, Javier Garcia-Corbacho, Erika Hamilton, Jason Incorvati, Peter Kabos, Mafalda Oliveira, Manish R Patel, Manuel Ruiz-Borregó, Nicholas Turner, Chris Twelves, Christos Vaklavas, Danielle Carroll, Steven Ching, Nevena Cvetesic, Michelle DuPont, Lisa Gibbons, Alastair Mathewson, Rhiannon Maudsley, Pablo Morentin Gutierrez, Avinash Reddy, Jaime Rodriguez-Canales, Susana Ros, Dhivya Sudhan, Andy Sykes, David Whitson, Teresa Klinowska, Justin Lindemann
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-07-13.
https://doi.org/10.1158/1538-7445.SABCS22-P3-07-13
Published: 01 March 2023
View article titled, Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α
Journal Articles

Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)

James S. Scott, Thomas Moss, Steve Stokes, Willem M. Nissink, Christopher J. Morrow, Mandy Lawson, Natalie Cureton, Eric Gangl, Pablo Morentin Gutierrez, Richard Mather, Justin P. Lindemann, Andrew Sykes, David Fisher, Radoslaw Polanski, Danielle Carroll, Aisling Barton Twomey, Teresa Klinowska
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5674.
https://doi.org/10.1158/1538-7445.AM2020-5674
Published: 15 August 2020
View article titled, Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)
Journal Articles

Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

Mandy Lawson, Natalie Cureton, Michelle DuPont, Oona Delpuech, Dawn Trueman, Pei Zhang, Azadeh Cheraghchi-Bashi-Astaneh, Sladjana Gagrica, Gareth Maglennon, Daniel Sutton, Bairu Zhang, Jonathan Cairns, Jamie Scott, Teresa Klinowska, Christopher J. Morrow
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 4379.
https://doi.org/10.1158/1538-7445.AM2020-4379
Published: 15 August 2020
View article titled, Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant
Journal Articles

Abstract 4369: Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development

Pablo Morentin Gutierrez, Christopher Morrow, Natalie Cureton, Mandy Lawson, Dawn Trueman, Eric Gangl, Joanne Wilson, Aaron Smith, James Scott, Teresa Klinowska
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 4369.
https://doi.org/10.1158/1538-7445.AM2020-4369
Published: 15 August 2020
View article titled, Abstract 4369: Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development
Journal Articles

Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

Mandy Lawson, Natalie Cureton, Oona Delpuech, Pei Zhang, Azadeh Cheraghchi-Bashi-Astaneh, Sladjana Gagrica, Dawn Trueman, Gareth Maglennon, Daniel Sutton, Bairu Zhang, Jonathan Cairns, Teresa Klinowska, Christopher J Morrow
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P6-04-15.
https://doi.org/10.1158/1538-7445.SABCS19-P6-04-15
Published: 15 February 2020
View article titled, Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects
Journal Articles

Abstract 321: Genome-wide CRISPR screens identify combination strategies for Capivasertib (AZD5363; AKT) and AZD8186 (PI3Kβ/δ) in PTEN-null breast cancer

Shanade Dunn, Jason Yu, Albert Gris-Oliver, James Pilling, Philip Hopcroft, Urs Yelland, Natalie Cureton, Anna Staniszewsla, Yan Zi Au, Swee Hoe Ong, Beverley Isherwood, Violeta Serra, Simon Barry, Barry R. Davies, James T. Lynch, Kosuke Yusa
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 321.
https://doi.org/10.1158/1538-7445.AM2019-321
Published: 01 July 2019
View article titled, Abstract 321: Genome-wide CRISPR screens identify combination strategies for Capivasertib (AZD5363; AKT) and AZD8186 (PI3Kβ/δ) in PTEN-null breast cancer